AKBA Q3 2025 Earnings — Akebia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

AKBAAkebia Therapeutics, Inc.

$365M

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$59M+57.0% YoY

Gross Profit

$49M83.5% margin

Operating Income

$4M7.6% margin

Net Income

$540,0000.9% margin

EPS (Diluted)

$0.00

QoQ Revenue Growth

-5.9%

Cash Flow

Operating Cash Flow

$28M

Free Cash Flow

$28M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$364M

Total Liabilities

$323M

Stockholders' Equity

$42M

Cash & Equivalents

$166M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$59M	$37M	+57.0%
Gross Profit	$49M	$23M	+110.9%
Operating Income	$4M	-$13M	+135.6%
Net Income	$540,000	-$20M	+102.7%

Revenue Segments

Product

$57M97%

License Collaboration And Other Revenue

$2M3%